UK Announces New Five-Year Voluntary Drug Pricing Deal
Executive Summary
The VPAG includes a gradual rise in allowable branded medicine sales to the NHS and differentiated payment mechanisms for older and newer products. Industry will also commit to invest £400m in “pioneering” clinical trials, innovative manufacturing, and novel approaches to health technology assessments.
You may also be interested in...
UK Government Reveals New Statutory Pricing Scheme
The scheme still includes high rebate rates, but a controversial life cycle adjustment mechanism has been dropped.
What’s Next? Five Things To Look Out For In December
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.
New UK Investment Facility To Boost Horizon-Scanning For Pipeline Drugs
An updated UK PharmaScan platform is to be delivered within the first three years of the new voluntary drug pricing scheme, with companies agreeing to provide “timely, accurate and comprehensive information” for all their medicines in development.